GC Biopharma (CEO Eun-cheol Heo) today announced positive Phase 2 results for its shingles vaccine, CRV-101 (ingredient name amezosvatein),’ which is being developed by its U.S. partner Curevo Vaccine.

The data represent top-line results from a head-to-head comparison of GSK's market-leading shingles vaccine, Shingrix, and CRV-101, which meets all primary endpoints and demonstrated non-inferiority and superior tolerability to GSK’s shingles vaccine Shingrix.

To evaluate the immunogenicity and safety of CRV-101, Curevo Vaccine inoculated 876 healthy adults aged 50 years and older with two different vaccines, at 2-month intervals, as the second booster shot.

The results sh